MedTrace Logo

Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial

NCT02784392 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-03-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect Ulimorelin in patients with enteral feeding intolerance.

Conditions

  • Enteral Feeding Intolerance (EFI)

Interventions

DRUG

Ulimorelin

Active

DRUG

Metoclopramide

Comparator

Sponsors & Collaborators

  • Lyric Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • M Scott Harris, MD · Lyric Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • United States
  • Netherlands
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02784392 on ClinicalTrials.gov